Dopaminergic Pathway Gene Polymorphisms and Genetic Susceptibility to Schizophrenia among North IndiansSrivastava V.a · Deshpande S.N.b · Thelma B.K.a
aDepartment of Genetics, University of Delhi South Campus, and bDepartment of Psychiatry, Dr. RML Hospital, New Delhi, India
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objective: Understanding the etiology and pathogenesis of schizophrenia has been difficult due to the complex inheritance patterns, genetic heterogeneity and varied multiple nonlinear interactions between genes. Several lines of evidence indicate the involvement of neurotransmitter dopamine in the pathophysiology of this disorder. To analyze such a possible role of dopaminergic pathway gene polymorphisms, we used a case-control approach. Method: We genotyped a total of 31 potential single nucleotide polymorphism/variable number of tandem repeat markers from 9 candidate genes including the dopamine receptors and metabolizing enzymes (synthesis and degradation) in 215 schizophrenia cases and 215 healthy controls from North India. Results: A nominally significant allelic association was observed in case of the catechol-O-methyltransferase rs362204 –/G (p = 0.028) marker whereas nominally significant genotypic associations were seen for tyrosine hydroxylase rs6356 A/G (p = 0.04) and dopamine β-hydroxylase rs1108580 A/G (p = 0.025) following the case-control approach. Several significant haplotypic associations were observed from dopamine β-hydroxylase, catechol-O-methyltransferase, and dopamine receptor D2 genes. A significant interaction of tyrosine hydroxylase rs6356 A/G and catechol-O-methyltransferase rs362204 –/G markers was also observed following binary logistic regression analysis (p = 0.009). Conclusions: A contribution of dopaminergic pathway gene polymorphisms to schizophrenia seems possible in our sample set. However, considering the marginal levels of associations, interpopulation comparisons and replicate studies are warranted.
© 2009 S. Karger AG, Basel
Gottesman II, Shields J: Schizophrenia: The Epigenetic Puzzle. Cambridge, Cambridge University Press, 1982.
Owen MJ, O’Donovan MC, Gottesman II: Schizophrenia; in McGuffin P, Owen MJ, Gottesman II (eds): Psychiatric Genetics and Genomics. Oxford, Oxford University Press, 2002, pp 247–266.
- Berry N, Jobanputra V, Pal H: Molecular genetics of schizophrenia: a critical review. J Psychiatry Neurosci 2003;28:415–429.
- Glenthoj BY, Hemmingsen R: Transmitter dysfunction during the process of schizophrenia. Acta Psychiatr Scand 1999;395 (suppl 1):105–112.
- Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA: Recent advances in the neurobiology of schizophrenia. Mol Interv 2003;3:27–39.
- Carlsson A: The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006;39(suppl 1):S10–S14.
- Carlsson A: The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179–186.
- Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27–38.
- Seeman P, Kapur S: Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA 2000;5;97:7673–7675.
- Sit SY: Dopamine agonists in the treatment of Parkinson’s disease past, present and future. Curr Pharm Des 2000;6:1211–1248.
- Abi-Dargham A: Dopamine abnormalities in schizophrenia. Eur Psychiatry 2002;17 (suppl 4):341–347.
- Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R: Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999;1;46:56–72.
- Laruelle M: The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 2000;31:371–384.
- Lewis DA, Lieberman JA: Catching up on schizophrenia: natural history and neurobiology. Neuron 2000;28:325–334.
- Murphy KC, Cardno AG, McGuffin P: The molecular genetics of schizophrenia. J Mol Neurosci 1996;7:147–157.
- Wong AHC, Buckle CE, Van Tol HHM: Polymorphisms in dopamine receptors: what do they tell us? Eur J Pharmacol 2000;410:183–203.
- Prasad S, Semwal P, Deshpande S, Bhatia T, Nimgaonkar VL, Thelma BK: Molecular genetics of schizophrenia: past, present and future. J Biosci 2002;27(1 suppl 1):35–52.
- Collier DA, Li T: The genetics of schizophrenia: glutamate not dopamine? Eur J Pharmacol 2003;480:177–184.
- Talkowski ME, Bamne M, Mansour H, Nimgaonkar VL: Dopamine genes and schizophrenia: case closed or evidence pending? Schizophr Bull 2007;33:1071–1081.
- Prasad S, Deshpande SN, Bhatia T, Wood J, Nimgaonkar VL, Thelma BK: Association study of schizophrenia among Indian families. Am J Med Genet 1999;88:298–300.
- Semwal P, Prasad S, Bhatia T, Deshpande SN, Wood J, Nimgaonkar VL, Thelma BK: Family-based association studies of monoaminergic gene polymorphisms among North Indians with schizophrenia. Mol Psychiatry 2001;6:220–224.
- Semwal P, Prasad S, Varma PG, Bhagwat AM, Deshpande SN, Thelma BK: Candidate gene polymorphisms among North Indians and their association with schizophrenia in a case-control study. J Genet 2002;81:65–71.
- Talkowski ME, Mansour H, Chowdari KV, Wood J, Butler A, et al: Novel, replicated associations between dopamine D3 receptor gene polymorphisms and schizophrenia in two independent samples. Biol Psychiatry 2006;15;60:570–577.
- Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T: Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994;51:849–859.
- Hotamisligil GS, Breakefield XO: Human monoamine oxidase A gene determines levels of enzyme activity. Am J Hum Genet 1991;49:383–392.
- Kunugi H, Kawada Y, Hattori M, Ueki A, Otsuka M, Nanko S: Association study of structural mutations of the tyrosine hydroxylase gene with schizophrenia and Parkinson’s disease. Am J Med Genet 1998;81:131–133.
- Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, Lerer B, Deshpande SN, Thelma BK: Genetic susceptibility to tardive dyskinesia among schizophrenia subjects. 4. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006;16:111–117.
- Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162–1169.
- Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978–989.
- Sham PC, Curtis D: Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995;59:97–105.
- Gordon D, Finch SJ, Nothnagel M, Ott J: Power and sample size calculations for case-control genetic association tests when errors present: application to single nucleotide polymorphisms. Hum Hered 2002;54:22–33.
Gordon D, Levenstien MA, Finch SJ, Ott J: Errors and linkage disequilibrium interact multiplicatively when computing sample sizes for genetic case-control association studies. Pac Symp Biocomput 2003:490–501.
- Nagatsu T, Levitt M, Udenfriend S: Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 1964;239:2910–2917.
- Kurumaji A, Kuroda T, Yamada K, Yoshikawa T, Toru M: An association of the polymorphic repeat of tetranucleotide (TCAT) in the first intron of the human tyrosine hydroxylase gene with schizophrenia in a Japanese sample. J Neural Transm 2001;108:489–495.
- Pae CU, Kim JJ, Serretti A, Lee CU, Lee SJ, Lee C, Paik IH: VNTR polymorphism of tyrosine hydroxylase gene and schizophrenia in the Korean population. Neuropsychobiology 2003;47:131–136.
- Hattori H, Shirakawa O, Nishiguchi N, Nushida H, Ueno Y, Maeda K: No evidence of an association between tyrosine hydroxylase gene polymorphisms and suicide victims. Kobe J Med Sci 2006;52:195–200.
- Yoshida K, Higuchi H, Takahashi H, Kamata M, Sato K, Inoue K, Suzuki T, Itoh K, Ozaki N: Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum Psychopharmacol 2008;23:121–128.
- Ota M, Nakashima A, Ikemoto K, Nojima S, Tanaka M, Okuda M, Koga H, Mori K, Kaneko YS, Fujiwara K, Yamamoto H, Nagatsu T, Ota A: Exon 3 of tyrosine hydroxylase gene: lack of association with Japanese schizophrenic patients. Mol Psychiatry 2001;6:315–319.
- Remington G: Understanding antipsychotic ‘atypicality’: a clinical and pharmacological moving target. J Psychiatry Neurosci 2003;28:275–284.
- Sanger DJ: The search for novel antipsychotics: pharmacological and molecular targets. Expert Opin Ther Targets 2004;8:631–641.
- Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000;97:8104–8109.
- Li T, Sham PC, Vallada HP, Xie T, Tang X, Liu X, et al: Preferential transmission of high activity allele of COMT in schizophrenia. Psychiatr Genet 1996;6:131–133.
- Strous RD, Bark N, Parsia SS, Volavka J, Lachman HM: Analysis of a functional COMT gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. Psychiatry Res 1997;69:71–77.
- Kunugi H, Vallada HP, Sham PC, Hoda F, Arranz MJ, Li T, Nanko S, Murray RM, Mc Guffin P, Owen M, Collier DA: Catechol- O-methyltransferase polymorphisms and schizophrenia: a transmission disequilibrium study in multiply affected families. Psychiatr Genet 1997;7:97–101.
- Lachman HM, Nolan KA, Mohr P, Saito T, Volavka J: Association between catechol O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorder. Am J Psychiatry 1998;155:835–837.
- Daniels JK, Williams J, Jones LA, Cardno AG, Murphy KC, Spurlock G, Riley B, Scambler P, Asherson P, Mc Guffin P, Owen MJ: No evidence for allelic associations between schizophrenia in a polymorphism determining high or low COMT activity. Am J Psychiatry 1996;153:268–270.
- Karayiorgou M, Gogos JA, Galke BL, Wolyniec PS, Nestadt G, Antonarakis SE, Kazazian HH, Housman DE, Pulver AE: Identification of sequence variants and analysis of the role of COMT gene in schizophrenia susceptibility. Biol Psychiatry 1998;43:425–431.
- Norton N, Kirov G, Zammit S, Jones G, Jones S, Owen R, et al: Schizophrenia and functional polymorphism in the MAO and COMT genes: no evidence for association or epistasis. Am J Med Genet 2002;114:491–496.
- Oka M, Kajikawa K, Ohuchi T, Yoshida H, Imaizumi R: Distribution of dopamine-beta-hydroxylase in subcellular fractions of adrenal medulla. Life Sci 1967;6:461–465.
- Kemper CM, O’Connor DT, Westlund KN: Immunocytochemical localization of dopamine-beta-hydroxylase in neurons of the human brain stem. Neuroscience 1987;23:981–989.
- Weinshilboum RM: Biochemical genetics of catecholamines in humans. Mayo Clin Proc 1983;58:319–330.
- Oxenstierna G, Edman G, Iselius L, Oreland L, Ross SB, Sedvall G: Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals – A genetic study. J Psychiatr Res 1986;20:19–29.
- Meltzer HY, Nasr SJ, Tong C: Serum dopamine-beta-hydroxylase activity in schizophrenia. Biol Psychiatry 1980;15:781–788.
- Arato M, Bagdy G, Blumel F, Perenyi A, Rihmer Z: Reduced serum dopamine-beta-hydroxylase activity in paranoid schizophrenics. Pharmacopsychiatria 1983;16:19–22.
- Sternberg DE, van Kammen DP, Lerner P, Ballenger JC, Marder SR, Post RM, Bunney WE Jr: CSF dopamine beta-hydroxylase in schizophrenia. Arch Gen Psychiatry 1983;40:743–747.
- van Kammen DP, Kelley ME, Gilbertson MW, Gurklis J, O’Connor DT: CSF dopamine beta-hydroxylase in schizophrenia: associations with premorbid functioning and brain computerized tomography scan measures. Am J Psychiatry 1994;151:372–378.
- Stanley WC, Li B, Bonhaus DW, Johnson LG, Lee K, Porter S, Walker K, Martinez G, Eglen RM, Whiting RL, Hegde SS: Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol 1997;121:1803–1809.
- Birnbaum SG, Podell DM, Arnsten AF: Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav 2000;67:397–403.
- Paclt I, Koudelova J: Changes of dopamine-beta-hydroxylase activity during ontogenesis in healthy subjects and in an experimental model (rats). Physiol Res 2004;53:661– 667.
- Cubells JF, van Kammen DP, Kelley ME, Anderson GM, O’Connor DT, Price LH, Malison R, Rao PA, Kobayashi K, Nagatsu T, Gelernter J: Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet 1998;102:533–540.
- Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE: Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 2003;23:2008–2013.
- Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science 1996;273:1516–1517.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.